Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Infectious Diseases |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317 |
Resumo: | ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients. |
id |
BSID-1_82d36cdb3cbf4bfcdf330e14d17f135e |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702018000400317 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in BrazilSofosbuvirDaclatasvirSimeprevirDAASustained virological responseABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients.Brazilian Society of Infectious Diseases2018-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317Brazilian Journal of Infectious Diseases v.22 n.4 2018reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2018.06.004info:eu-repo/semantics/openAccessHolzmann,IandraTovo,Cristiane V.Minmé,RoselineLeal,Mônica P.Kliemann,Michele P.Ubirajara,CamilaAquino,Amanda A.Araujo,BrunaAlmeida,Paulo R.L.eng2018-10-09T00:00:00Zoai:scielo:S1413-86702018000400317Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2018-10-09T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
title |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
spellingShingle |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil Holzmann,Iandra Sofosbuvir Daclatasvir Simeprevir DAA Sustained virological response |
title_short |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
title_full |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
title_fullStr |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
title_full_unstemmed |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
title_sort |
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil |
author |
Holzmann,Iandra |
author_facet |
Holzmann,Iandra Tovo,Cristiane V. Minmé,Roseline Leal,Mônica P. Kliemann,Michele P. Ubirajara,Camila Aquino,Amanda A. Araujo,Bruna Almeida,Paulo R.L. |
author_role |
author |
author2 |
Tovo,Cristiane V. Minmé,Roseline Leal,Mônica P. Kliemann,Michele P. Ubirajara,Camila Aquino,Amanda A. Araujo,Bruna Almeida,Paulo R.L. |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Holzmann,Iandra Tovo,Cristiane V. Minmé,Roseline Leal,Mônica P. Kliemann,Michele P. Ubirajara,Camila Aquino,Amanda A. Araujo,Bruna Almeida,Paulo R.L. |
dc.subject.por.fl_str_mv |
Sofosbuvir Daclatasvir Simeprevir DAA Sustained virological response |
topic |
Sofosbuvir Daclatasvir Simeprevir DAA Sustained virological response |
description |
ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjid.2018.06.004 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.22 n.4 2018 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209244571238400 |